#Biopharma

Tom DiLenge

TomDilenge

In my piece last week for @InsideSourcesDC, I discuss the importance of respecting IP protections for the innovators leading the response to #COVID-19, and that we must support the #biotech

Shiektal

shiektal

$CMLF / $CMLF and @sema4 - Deep dive on my largest position post merger announcement. I was expecting a more focused company, stagewise, as the target but am very excited

Dr. Ali Nouri

AliNouriPhD

The science pledge by vaccine manufacturers falls short because it leaves open the possibility of a pre-election Emergency Use Authorization for a vaccine. That would be viewed as political and

Deep Barot

deepbarot

Important thread on latest developments in #COVID19 vaccine race, thread also breaks down my investment picks as requested. Right now (in the US):1. Moderna- Phase II (Clinical Trials), NIAD partnership2.

Sara Nayeem

SaraNayeem

Suggestions for biopharma co’s on positioning BD efforts to investors: 1) Don’t suggest that you’ll partner out your lead program. Generally inv’s will appreciate licensing deals for the revenue they

thisisFET

ThisisFet

Considering your options ahead of the CAO deadline? Maybe you've decided what you want to study, but have you considered all the options for *how* you might study? No matter

Ryan Reeves

investing_city

Genomics Thread #6Let's talk about liquid biopsies... 1/ A liquid biopsy is usually a blood-based test that can detect cancer. How?By detecting either CTC (circulating tumor cells) or ctDNA (circulating

Sara Nayeem

SaraNayeem

Academic-led early stage biopharma co's, particularly those that haven't yet raised institutional capital, can face a chicken-and-the-egg issue. They may need an experienced operator to help refine strategy & kickstart

Ryan Reeves

investing_city

Genomics Thread #5We've already laid the groundwork for understanding DNA, and some parts of the sequencing value chain but now let's talk about genetic testing... 1/ You can think of

sediment

so_i_am_george

I saw a tweet related to this the other day but I can't find it so here we go. The strange relationship between science, media, and the general public is

Peter Kolchinsky

PeterKolchinsky

Some people think we overpay for only incrementally better medicines. That only home runs deserve high prices. But as in baseball- most are trying as hard as they can &

𝓝𝓸𝓼𝓯𝓮𝓻𝓪𝓽𝓾

FourWinns298

1/The main vaccine candidates' race for approval is almost finished and now we need them all available to every country with open sharing of the processes for production, quality assurance,

Ethan Perlstein

eperlste

Noticing some interesting new trends among @ycombinator S20 bio companies that speak to a new kind of biotech founder and a new kind of biotech investor. Founders are the most

Greg

greg_scott84

CONNECTING MORE DOTS1) What do gun control, vaccines, carbon taxes, and WE Charity all have in common? 2) All four of these have very important connections to the UN Sustainable

Jorge Conde

JorgeCondeBio

1/ Biotech is a tough business. There are 10,000+ human diseases out there. How do startups w/ promising platforms choose where to focus?Choose wisely. @andy23tran @a16z & I offer a

Vinay Prasad MD MPH

VPrasadMDMPH

A few predictions as to what happens to the process of science/ med after COVID whimpers to an end1. The Journal market for COVID publications is going to hit rock

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.